We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

64 hedge funds and large institutions have $73.3M invested in ARS Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.67% less ownership

Funds ownership: 76.81% → 74.14% (-2.7%)

9% less funds holding

Funds holding: 70 → 64 (-6)

12% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 26

23% less capital invested

Capital invested by funds: $94.7M → $73.3M (-$21.4M)

28% less call options, than puts

Call options by funds: $2.92M | Put options by funds: $4.07M

39% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 23

Holders
64
Holders Change
-6
Holders Change %
-8.57%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
14
Reduced
23
Closed
26
Calls
$2.92M
Puts
$4.07M
Net Calls
-$1.15M
Net Calls Change
-$1.33M

Top Buyers

1
KPF
K2 Principal Fund
Ontario, Canada
+$5.38M
2
RCMNY
Rubric Capital Management (New York)
New York
+$3.44M
3
NCM
Nantahala Capital Management
Connecticut
+$1.65M
4
Millennium Management
Millennium Management
New York
+$1.59M
5
OMC
Oasis Management Company
Cayman Islands
+$1.11M

Top Sellers

1
WA
Wasatch Advisors
Utah
-$10.4M
2
BlackRock
BlackRock
New York
-$3.14M
3
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$1.22M
4
State Street
State Street
Massachusetts
-$965K
5
Two Sigma Investments
Two Sigma Investments
New York
-$724K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$15.8M -$261K -74,720 -2%
NI
2
Nextech Invest
Switzerland
$8.1M – – –
KPF
3
K2 Principal Fund
Ontario, Canada
$6.54M +$5.38M +1,541,706 New
NCM
4
Nantahala Capital Management
Connecticut
$5.88M +$1.65M +472,541 +52%
Vanguard Group
5
Vanguard Group
Pennsylvania
$4.48M +$814K +233,368 +28%
RCMNY
6
Rubric Capital Management (New York)
New York
$4.18M +$3.44M +986,453 New
BlackRock
7
BlackRock
New York
$3M -$3.14M -899,655 -56%
EC
8
EcoR1 Capital
California
$2.44M +$857K +245,822 +75%
Renaissance Technologies
9
Renaissance Technologies
New York
$2.33M -$423K -121,243 -18%
Millennium Management
10
Millennium Management
New York
$1.93M +$1.59M +455,051 New
Two Sigma Advisers
11
Two Sigma Advisers
New York
$1.81M +$195K +55,900 +15%
PM
12
Prosight Management
Texas
$1.45M +$54.9K +15,743 +5%
OMC
13
Oasis Management Company
Cayman Islands
$1.35M +$1.11M +317,662 New
Bank of America
14
Bank of America
North Carolina
$1.03M -$71.2K -20,425 -8%
Morgan Stanley
15
Morgan Stanley
New York
$1.01M -$517K -148,340 -38%
Citadel Advisors
16
Citadel Advisors
Florida
$982K +$127K +36,510 +19%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$948K -$485K -138,988 -38%
SCM
18
Silverarc Capital Management
Massachusetts
$887K +$729K +209,108 New
Two Sigma Investments
19
Two Sigma Investments
New York
$820K -$724K -207,676 -52%
AAA
20
Affinity Asset Advisors
New York
$721K +$593K +170,000 New
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$705K -$469K -134,374 -45%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$643K +$529K +151,582 New
NYLIM
23
New York Life Investment Management
New York
$563K +$463K +132,860 New
Goldman Sachs
24
Goldman Sachs
New York
$523K +$75.3K +21,595 +21%
Charles Schwab
25
Charles Schwab
California
$452K -$143K -40,961 -28%
1
2 3 4

SPRY Hedge Fund Activity: Q2 2022 in Review

64 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2022, worth a combined $73.3M — down 23% from $94.7M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SPRY and 23 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 14 added.

The largest buyer was K2 Principal Fund, opening a new position worth an estimated $5.38M. The largest seller was Wasatch Advisors, exiting entirely with an estimated $10.4M sold.

  • 64 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2022, down from 70 in Q1 2022.
  • Funds reported $73.3M of ARS Pharmaceuticals stock for Q2 2022, down 23% quarter-over-quarter.
  • 23 funds opened new ARS Pharmaceuticals positions in Q2 2022 and 26 closed out, a net change of -3 holders.
  • The largest ARS Pharmaceuticals buyer in Q2 2022 was K2 Principal Fund, an estimated $5.38M added.
  • The largest ARS Pharmaceuticals seller in Q2 2022 was Wasatch Advisors, an estimated $10.4M sold.

Based on aggregated 13F filings for Q2 2022.